Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+therapeutic+delivery+platforms

110 Results

Sort By:

Polymeric particles for sustained delivery of multimodal peptide therapeutics

Polymeric particles for sustained delivery of multimodal peptide therapeutics JHU Ref #: C11250 Value Proposition · Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects · Safety: use of nanoparticles...

Published: 10/27/2025 | Inventor(s): Jordan Green, Aleksander Popel, Joel Sunshine, Ron Shmueli, Stephany Tzeng, Kristen Kozielski

Keywords(s): Biologics, Drug Delivery Vehicle, Nucleic Acid, Peptide, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities

Cationic Polymers with Biphasic Biodegradation

Value Proposition· Delivery Efficacy: Demonstrates more effective gene delivery to cancer associated fibroblasts (CAFs) or human primary fibroblasts than industry gold-standards such as Lipofectamine 2000 and polyethylenimine (PEI).· Cargo Compatibility: Enables encapsulation and delivery of a wide range of cargos including, DNA, RNA,...

Published: 10/23/2025 | Inventor(s): Stephany Tzeng, Ron Shmueli, Nupura Bhise, Joel Sunshine, Jordan Green

Keywords(s): Drug Delivery Vehicle, Polymers, Therapeutic Matter, Therapeutics

A method for inhibiting UHRF1 in colorectal cancer

Value PropositionReversal of colorectal cancer-specific DNA hypermethylationmRNA-based strategy for UHRF1 inhibitionA lipid nanoparticle-based delivery platformUnmet Need1 out of 24 people will develop colorectal cancer. Current technologies do not maximize the bodies’ native ability to suppress tumors. Existing therapies lack specificity and cause...

Published: 10/24/2025 | Inventor(s): Stephen Baylin, Srinivasan Yegnasubramanian, Ying Cui, Xiangqian Kong

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Research Tools > Proteins, Ligands & Receptors

Lipid Nanoparticle Formulations Capable of Migrating to Systemic Organs Following Intramuscular Administration

Value Proposition:Organ-targeted drug or mRNA delivery to focus therapy on specific tissues. Accessible intramuscular administration, offering broadly applicable, out-of-the-box drug delivery system for a range of therapeutics.Achieves organ-specific delivery without antibodies or targeting ligands, simplifying manufacturing and scalability.Unmet NeedTargeting...

Published: 10/24/2025 | Inventor(s): Hai-Quan Mao, Yining Zhu, Christine Wei, Di Yu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Facile Methods to Attenuate PDMS Drug Absorption

Value Proposition· Increased efficacy: This method effectively eliminates PDMS's drug adsorption property while preserving its beneficial characteristics, making this discovery potentially transformative for any drug efficacy and toxicity studies utilizing microfluidic devices.· Widely applicable: This approach has broader implications...

Published: 10/24/2025 | Inventor(s): Devin Mair, Marcus Williams, Jeffrey Chen, Deok-Ho Kim

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Methods and formulations for engineered peptide conjugates for sustained intraocular drug delivery

JHU Ref #: C17191Value Proposition· Reducing the number of daily eye drop doses required for therapeutic effect in the posterior chamber· Limited systemic absorption of medication delivered via topical eyedrops Unmet Need· The mainstay of medication delivery to the eye remains topical eye-drops. While intravitreal injections have been...

Published: 10/24/2025 | Inventor(s): Laura Ensign, Tung Heng Hsueh, Renee Chou, Michael Cummings, Justin Hanes

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Computers, Electronics & Software > Machine Learning, Clinical and Disease Specializations > Ophthalmology

Extracellular Vesicle mediated nucleic acid treatment in vivo

Value Proposition· Effective: animal studies showed increased survival and decreased tumor burden in liver cancer model.· Fewer side effects: no immunological reactions or off-target effects· Multiple targets: targets the cancer-stroma interactionsUnmet Need· Many current and pipeline cancer therapeutics, including therapeutic...

Published: 10/23/2025 | Inventor(s): Ling Li, Stephen Gould, Florin Selaru

Keywords(s): Drug Delivery Vehicle, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

A mRNA Lipid Nanoparticle Incorporated Nanofiber-hydrogel Composite to Generate a Local Immunostimulatory Niche for Immunotherapy

Value Proposition:· Creates a programmable immunostimulatory niche.· Allows for tailor-made immune responses to vaccines and antigens.· Flexible drug delivery platform enables mRNA therapeutics for infectious diseases and cancers.· Applicable to existing mRNA vaccines for improved efficacy. · Can be utilized for novel...

Published: 10/24/2025 | Inventor(s): Hai-Quan Mao, Yining Zhu, Jingyao Ma, Zhicheng Yao, Christine Wei

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Research Tools, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Research Tools > Microfluidics

Kinetically controlled methods to prepare concentrated shelf-stable nucleic acid transfection vehicles

Value Proposition:· Technology creates particles optimally size for use as vehicles for cell transfection.· The reagents and processes for particle creation are kinetically controlled and reproducible.· Cationic particles created using these methods can carry larger payloads than current vehicles.· Reagents and nucleic acid-loaded...

Published: 10/24/2025 | Inventor(s): Hai-Quan Mao, Yizong Hu, Jinghan Lin

Keywords(s):

Nanofiber Hydrogel Composite Gel to Prevent Scarring and Adhesion of Peripheral Nerves

JHU Ref #: [C17294] Value Proposition:· Application of composite hydrogel to mechanically irritated nerves can reduce perineural adhesions and scar formation.· Improves patient outcomes following peripheral nerve surgery. Technology Description· Researchers at Johns Hopkins have developed a nanofiber-hydrogel composite (NHC) material...

Published: 10/24/2025 | Inventor(s): Hai-Quan Mao, Sami Tuffaha, Sashank Reddy, Visakha Suresh, Thomas Harris, Chenhu Qiu

Keywords(s):

Category(s): Technology Classifications, Technology Classifications > Medical Devices > Plastic Surgery, Technology Classifications > Medical Devices > Regenerative Medicine, Technology Classifications > Medical Devices > Surgery, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Engineering Tech > Materials, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers

1 2 3 4 5 6 7 8 9 10 ...